KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Common Equity (2016 - 2025)

Teva Pharmaceutical Industries' Common Equity history spans 17 years, with the latest figure at $7.9 billion for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 47.1% year-over-year to $7.9 billion, compared with a TTM value of $7.9 billion through Dec 2025, up 47.1%, and an annual FY2025 reading of $7.9 billion, up 47.1% over the prior year.
  • Common Equity for Q4 2025 was $7.9 billion at Teva Pharmaceutical Industries, up from $7.3 billion in the prior quarter.
  • The five-year high for Common Equity was $11.5 billion in Q3 2021, with the low at $5.4 billion in Q4 2024.
  • Average Common Equity over 5 years is $8.4 billion, with a median of $8.0 billion recorded in 2023.
  • Year-over-year, Common Equity crashed 33.79% in 2024 and then skyrocketed 47.1% in 2025.
  • Tracing TEVA's Common Equity over 5 years: stood at $11.2 billion in 2021, then dropped by 23.53% to $8.6 billion in 2022, then dropped by 5.49% to $8.1 billion in 2023, then plummeted by 33.79% to $5.4 billion in 2024, then surged by 47.1% to $7.9 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Common Equity are $7.9 billion (Q4 2025), $7.3 billion (Q3 2025), and $6.8 billion (Q2 2025).